Chi-Med appoints Industry Veteran Paul Carter to Board of Directors
January 16 2017 - 5:23AM
Business Wire
Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM)
today announces with effect from February 1, 2017, Mr Paul
Rutherford Carter has been appointed as Senior Independent
Non-Executive Director and member of the Audit Committee,
Remuneration Committee and Technical Committee of Chi-Med; and Mr
Shigeru Endo tendered his resignation as Non-executive Director and
Mr Christopher Nash tendered his resignation as Senior Independent
Non-executive Director and member of Audit Committee and
Remuneration Committee effective on the same date.
Mr Carter, aged 56, has more than 25 years of experience in the
pharmaceutical industry. From 2006 to 2016, Mr Carter served in
various senior executive roles at Gilead Sciences, Inc. (“Gilead”),
a research-based biopharmaceutical company, with the last position
as Executive Vice President, Commercial Operations. In this role Mr
Carter headed the worldwide commercial organisation responsible for
the launch and commercialisation of all of Gilead’s products. Prior
to joining Gilead, he spent 14 years with GlaxoSmithKline PLC (GSK)
and its group companies, with the last position as a Regional Head
of the International business in Asia.
Mr Carter is currently a director of Alder Biopharmaceuticals,
Inc. He was previously a director of Gilead Sciences Ltd, Gilead
Sciences International Ltd. and Gilead Sciences Europe Ltd. within
the past five years.
Mr Carter holds a degree in Business Studies from the Ealing
School of Business and Management (now merged into University of
West London) and is a Fellow of the Chartered Institute of
Management Accountants in the UK.
He does not have any shareholdings in Chi-Med. Save for the
information disclosed above, there is no other information in
relation to Mr Carter that is required to be disclosed pursuant to
Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Mr Simon To, Chairman of Chi-Med said “We thank Mr Shigeru Endo
and Mr Christopher Nash for their invaluable contributions to the
Company during their tenure and welcome Mr Carter to the Board
whose experience in the global biopharmaceutical industry will be
important to the Company.”
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect Chi-Med’s current expectations regarding future
events. Forward-looking statements involve risks and uncertainties.
Such risks and uncertainties include, among other things, the risk
that current or future appointees to Chi-Med’s board of directors
are not effective in their respective positions, the difficulty in
locating and recruiting suitable candidates for its board of
directors and the management difficulties which may arise from
changes in Chi-Med’s board of directors. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
For further discussion of these and other risks, see Chi-Med’s
filings with the U.S. Securities and Exchange Commission and on
AIM. Chi-Med undertakes no obligation to update or revise the
information contained in this announcement, whether as a result of
new information, future events or circumstances or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170116005310/en/
Chi-MedInvestor EnquiriesChristian Hogg, CEO+852
2121 8200orInternational Media EnquiriesAnthony Carlisle,
Citigate Dewe Rogerson+44 7973 611 888
(Mobile)anthony.carlisle@cdrconsultancy.co.ukorU.S. Based Media
EnquiriesBrad Miles, BMC Communications+1 (917) 570 7340
(Mobile)bmiles@bmccommunications.comorSusan Duffy, BMC
Communications+1 (917) 499 8887
(Mobile)sduffy@bmccommunications.comorInvestor RelationsMatt
Beck, The Trout Group+1 (917) 415 1750
(Mobile)mbeck@troutgroup.comorDavid Dible, Citigate Dewe
Rogerson+44 7967 566 919
(Mobile)david.dible@citigatedr.co.ukorPanmure Gordon (UK)
LimitedRichard Gray / Andrew Potts+44 (20) 7886 2500
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024